Piccirillo F, Caiazzo G, Miglionico M, et al. - Researchers sought to compare clinical results of all-comer patients receiving percutaneous coronary intervention (PCI) with new generation durable-polymer drug-eluting stents (DP-DES) or reabsorbable-polymer (RP)-DES implantation. The 1-year incidence of major adverse clinical events (MACE), defined as a composite of death, myocardial infarction (MI), and target vessel revascularization (TVR), was assessed as the primary endpoint. This study included 439 (64.6%) patients who received RP-DES and 240 (36.4%) who received DP-DES. In terms of the incidence of MACE, death, MI, TVR, target lesion revascularization, and definite stent thrombosis, there was no significant difference between RP-DES and DP-DES groups at 1-year follow-up. Overall, findings demonstrated similar efficacy as well as safety, at a 1-year follow-up, of RP-DES vs durable polymer-DES in this registry incorporating a real-world population of all-comer patients receiving PCI.